We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2013 by Stanford University.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01060319
First Posted: February 2, 2010
Last Update Posted: October 14, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
National Institutes of Health (NIH)
Providence Foundation
Information provided by (Responsible Party):
Stanford University
  Purpose
We hypothesize that all human malignancies harbour a subpopulation of tumor initiating cells/cancer stem cells (CSCs) that drives tumor development and potentially recurrence or metastasis of the disease. The primary aim of this study is to develop strategies for prospective isolation/enrichment of CSCs from human tumors of different tissue origins. In addition, we will characterize the signaling pathways and/or tumor specific antigens that are specific for CSCs, in order to specifically target these CSCs as the endpoint of this study.

Condition
Bladder Cancer Skin Cancers Bladder (Urothelial, Transitional Cell) Cancer Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Measurement of cancer stem cells (CSCs) [ Time Frame: The current study does not include the active involvement of patients. Our study involves the collection of tumor samples from patients after surgical procedures. ]

Biospecimen Retention:   Samples With DNA
Bladder cancer specimens

Estimated Enrollment: 40
Study Start Date: December 2013
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
non-melanoma skin and bladder cancer patients that are recommended for surgical removal of tumor tissues
Criteria

Inclusion Criteria:N/A. We will recruit all non-melanoma skin and bladder cancer patients that are recommended for surgical removal of tumor tissues. This includes patients from all ages, gender and ethnicity background. Our sample collection criteria based on the tumor size of individual (e.g. tumor samples will only be collected if it will not affect the pathological diagnosis or treatment procedures of patients).

Exclusion Criteria:N/A

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01060319


Locations
United States, California
Stanford University School of Medicine Not yet recruiting
Stanford, California, United States, 94305
Contact: Linda Quinn    650-723-6520    ljquinn@stanford.edu   
Contact: Cancer Clinical Trials Office    (650) 498-4073    ljquinn@stanford.edu   
Principal Investigator: Irving L. Weissman M.D.         
Sub-Investigator: Joseph C. Liao         
Sub-Investigator: Hayes Gladstone         
Sub-Investigator: Robert Chin         
Sponsors and Collaborators
Stanford University
National Institutes of Health (NIH)
Providence Foundation
Investigators
Principal Investigator: Irving L. Weissman M.D. Stanford University
  More Information

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT01060319     History of Changes
Other Study ID Numbers: BLDR0011
SU-11062009-4360 ( Other Identifier: Stanford University )
First Submitted: January 29, 2010
First Posted: February 2, 2010
Last Update Posted: October 14, 2013
Last Verified: October 2013

Additional relevant MeSH terms:
Urinary Bladder Neoplasms
Skin Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Skin Diseases